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The objectives of this study were to examine the involvement of
D1 and D2 receptors within the nucleus accumbens (ACB) in
mediating reinforcement. The intracranial self-administration
(ICSA) of D1 and D2 agonists was used to determine whether
activating D1 and/or D2 receptors within the ACB of Wistar rats
is reinforcing. At concentrations of 0.25, 0.50, and 1.0 mM (25,
50, and 100 pmol/100 nl of infusion), neither the D1 agonist
R(1)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
[SKF 38393 (SKF)] hydrochloride nor the D2 agonist (2)-
quinpirole (Quin) hydrochloride was self-administered into the
shell region of the ACB. On the other hand, equimolar mixtures
of SKF and Quin (SKF1Quin), at concentrations of 0.25, 0.50,
and 1.0 mM each, were significantly self-infused into the ACB
shell. The core region of the ACB did not support the ICSA of
SKF1Quin at any of these concentrations. Rats increased lever
pressing when the response requirement was increased from a
fixed ratio 1 (FR1) to FR3, and they responded significantly
more on the infusion lever than they did on the control lever.
Coadministration of either 0.50 mM R(1)-7-chloro-8-hydroxy-3-
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH
23390) hydrochloride, a D1 antagonist, or 0.50 mM S(2)-
sulpiride, a D2 antagonist, completely abolished the ICSA of the
mixture of SKF1Quin (each at 0.50 mM) into the ACB shell. The
present results suggest that concurrent activation of D1- and
D2-type receptors in the shell of the ACB had a cooperative
effect on DA-mediated reward processes.
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Dopamine (DA) systems of the brain have been implicated in
mediating reward-related behavior (see Fibiger and Phillips,
1986; Koob and Bloom, 1988; Wise and Rompre, 1989; Le Moal
and Simon, 1991). In particular, the DA pathway projecting from
the ventral tegmental area (VTA) to the nucleus accumbens
(ACB) is thought to play a major role in mediating the rewarding
effects of many stimuli, such as electrical brain stimulation and
drugs of abuse (see Wise and Bozarth, 1987; Di Chiara, 1995).
ACB DA depletion, produced by 6-OHDA, abolishes or attenu-
ates intravenous self-administration of the indirect DA agonists
amphetamine and cocaine (Roberts et al., 1977; Lyness et al.,
1979; Pettit et al., 1984). Microinjection of DA antagonists into
the ACB disrupts operant responding maintained by electrical
brain stimulation (Mora et al., 1975; Mogenson et al., 1979;
Stellar et al., 1983; Stellar and Corbett, 1989) and food (Ikemoto
and Panksepp, 1996). Amphetamine microinfused into the ACB
facilitates brain electrical self-stimulation (Broekkamp et al.,
1975; Colle and Wise, 1988) and produces place-preference con-
ditioning (Carr and White, 1983, 1986). Moreover, rats self-
administer amphetamine (Hoebel et al., 1983; Phillips et al.,
1994) and the DA uptake inhibitor nomifensine (Carlezon et al.,
1995) directly into the ACB.
The interaction of DA D1 and D2 receptors has been reported
for a number of electrophysiological and behavioral measures
(see Clark and White, 1987; Waddington et al., 1994). In the
ACB, synergistic effects of D1 and D2 agonists have been reported
for locomotor activity (Dreher and Jackson, 1989; Essman et al.,
1993; Koshikawa et al., 1996a), jaw movements (Cools et al., 1995;
Koshikawa et al., 1996b), and neuronal firing (White, 1987).
However, there is no clear information whether the interaction of
D1 and D2 receptors within the ACB can produce a cooperative
or synergistic effect on reinforcement processes. In addition, it is
not clear whether activating DA receptors within the shell and/or
core of the ACB is reinforcing. There is evidence that the shell
portion of the ACB is involved in mediating reward because both
amphetamine (Hoebel et al., 1983) and nomifensine (Carlezon et
al., 1995) were self-infused in this subregion. However, there is
also evidence that amphetamine could be self-infused into the
core portion of the ACB (Phillips et al., 1994).
Therefore, one objective of the present study was to determine,
using the intracranial self-administration (ICSA) technique,
whether activation of both D1 and D2 receptors was required for
the processing of reward-relevant information mediated by DA
within the ACB. A second objective was to determine whether
processing of this information occurred in the shell and/or core of
the ACB.
MATERIALS AND METHODS
Subjects
Experimentally naive, female Wistar rats (weighing 250–300 gm at the
time of surgery) were obtained from Harlan Industries (Indianapolis,
IN). Female rats were used in the present study because their growth rate
maintained their size within a range that aided the stereotaxic place-
ments (Ikemoto et al., 1997). Although not systematically examined, the
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estrous cycle did not seem to have any obvious effect on ICSA behavior
in this or a previous study (Ikemoto et al., 1997). Animals were singly
housed and maintained on a 12 hr light /dark cycle (lights on at 9:00
A.M.) with constant temperature and relative humidity. Food and water
were available ad libitum except in the test chamber. The treatments of
the subjects were approved by the institutional review board and are in
accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Test agents
R(1)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol (SKF 38393)
HCl, (2)-quinpirole HCl (LY 171555), R(1)-7-chloro-8-hydroxy-3-methyl-
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH 23390) HCl, and
S(2)-sulpiride were purchased from Research Biochemicals (Natick, MA).
Test agents were dissolved in an artificial CSF (aCSF) consisting of (in
mM): 120.0 NaCl, 4.8 KCl, 1.2 KH2PO4 , 1.2 MgSO4 , 25.0 NaHCO3 , 2.5
CaCl2 , and 10.0 D-glucose. When necessary, the pH was adjusted to 7.3 6
0.2 with 0.1 M HCl.
Apparatus
The apparatus used in the present study has been described previously
(Ikemoto et al., 1997). The operant chamber (30 cm in width 3 30 cm in
height 3 26 cm in depth) was equipped with two identical levers (3.5 3
1.8 cm) and was situated in a sound-attenuating cubicle (64 3 60 3 50
cm; Coulbourn Instruments, Inc., Allentown, PA) with a ventilating fan.
A dim house light illuminated the operant chamber during testing.
Unintended lever presses by the rat brushing against the levers or
stepping on them were avoided by mounting the levers 15 cm above the
grid floor and by separating them by 12 cm. This arrangement required
rats to rear to press the levers. The delivery of infusate in relation to
lever responses was controlled by a personal computer equipped with an
operant control system (L2T2 system; Coulbourn Instruments, Inc.).
An electrolytic microinfusion transducer (EMIT) system (see Cris-
well, 1977; Bozarth and Wise, 1980; Goeders and Smith, 1987) was used
for infusing the test agents. Briefly, two platinum electrodes were placed
in an infusate-filled cylinder (28 mm in length 3 6 mm in diameter)
equipped with a 28 gauge injection cannula (C323ICT; Plastic One,
Roanoke, VA). The electrodes were connected via spring-protected cable
(Plastic One) and a swivel (Model 205; Mercotac, Inc., Carlsbad, CA) to
a constant current generator (MNC, Inc.; Shreveport, LA), which deliv-
ered 6 mA of quiescent current and 200 mA of infusion current between
the electrodes. Depression of the infusion lever activated the constant
current generator and delivered the infusion current for 5 sec, which led
to the rapid generation of H2 gas in the gas tight cylinder and, in turn,
forced 100 nl of the infusate through the injection cannula.
Animal preparation
Under Halothane anesthesia, a unilateral 22 gauge guide cannula
(C313G; Plastic One) was stereotaxically implanted in the right hemi-
sphere of each subject and aimed 1.0 mm above the shell or core of the
ACB. The coordinates for the shell were 1.8 mm anterior to bregma, 3.4
mm lateral to the midline with a 16° lateral angle to the vertical, and 7.6
mm ventral from the skull surface. The coordinates for the core were 1.8
mm anterior to bregma, 4.0 mm lateral to the midline with a 16° lateral
angle to the vertical, and 7.0 mm ventral from the skull surface. The
incisor bar was set at 23.3 mm below horizontal zero (Paxinos and
Watson, 1986). When the system was not in use, a 28 gauge stylet
(C313DC; Plastic One) was inserted and extended 0.5 mm beyond the tip
of the guide cannula.
At least 7 d were allowed for recovery from the surgery, during which
animals were brought daily to the testing room and handled for 5 min. On
the day before the experimental sessions were started, subjects were
placed in the test chamber for 30 min to acclimate them to the novel
environment.
General test condition
To obtain stable voltage readings with the different test solutions, it was
necessary to condition the electrodes before starting the test sessions. To
accomplish this, electrodes were placed in the test solution, and the
quiescent current was applied overnight. Immediately before a test ses-
sion was started, the infusate was replaced with a fresh solution. All test
sessions were conducted during the light phase of the cycle.
Subjects were brought to the testing room and were placed individually
in the operant chambers. To avoid trapping air at the tip of the injection
cannula and to minimize clogging of the injector tip, we delivered the
infusion current for 5 sec as the injection cannula was inserted into the
guide cannula. The injection cannula extended 1.0 mm beyond the tip of
the guide. Depression of the infusion lever resulted in the delivery of 100
nl of infusate over a 5 sec period followed by a time-out period (60 sec
for experiments 1, 2, and 4, and 5 sec for experiment 3), during which
depression of the infusion lever produced no programmed consequence.
Depression of the control lever had no programmed consequence at any
time. The assignment of infusion and control levers with respect to the
left and right locations was counterbalanced among subjects. For each
subject, however, the assignment of the levers remained the same
throughout the experiment. No shaping technique was used to facilitate
the acquisition of lever responses. The number of infusions and re-
sponses on the infusion and control levers (including responses during
the time-out period) were recorded.
General test procedure for experiments 1, 2, and 4
An infusion was delivered contingent to the depression of the infusion
lever, which was followed by a 60 sec time-out period. The session lasted
for 3 hr but was terminated early if rats self-administered 40 infusions.
Sessions were separated by 48–72 hr.
Experiment 1, intra-ACB self-administration of D1 and D2
agonists: dose–response analyses
Rats with a cannula placement in the shell were assigned one of three
infusate treatments: the D1 agonist SKF 38393 alone (SKF), the D2
agonist quinpirole alone (Quin), or a mixture of SKF 38393 and quin-
pirole (SKF1Quin). Rats with cannula placements in the core received
only the mixture of SKF1Quin. During four sessions, the animals were
given the opportunity to self-infuse four concentrations (0.0, 0.25, 0.50,
and 1.0 mM) of the test solution. These concentrations produced infu-
sions of 0, 25, 50, and 100 pmol/100 nl of the individual SKF and Quin
solutions or 25, 50, and 100 pmol each of SKF and Quin in 100 nl of the
mixture (SKF1Quin). The order of testing different concentrations and
vehicle was counterbalanced among subjects. A one-way within-subject
design ANOVA followed by a Newman–Keuls test was conducted on the
data obtained with the four different concentrations.
Experiment 2, intrashell self-administration of D1 and D2
agonists: an interactive effect
Experimentally naive rats with a cannula placement in the shell were
assigned to one of three groups for intrashell self-administration of the
DA agonists. The SKF group received infusions of 0.5 mM SKF alone
during the first three sessions and infusions of 0.5 mM SKF plus 0.5 mM
Quin for sessions 4 and 5. The Quin group was given 0.5 mM Quin for
sessions 1–3 and 0.5 mM SKF plus 0.5 mM Quin in sessions 4 and 5. The
SKF1Quin group received infusions of 0.5 mM SKF plus 0.5 mM Quin
for sessions 1–3 and infusions of vehicle in session 4; 0.5 mM SKF plus 0.5
mM Quin was reinstated in session 5. To evaluate differential effects of
these three infusate treatments among the three groups, we conducted a
three 3 three mixed ANOVA on infusions with the three groups (SKF
vs Quin vs SKF1Quin groups) over the first three sessions. Differences
in infusion levels after the introduction of 0.5 mM SKF plus 0.5 mM Quin
in the SKF and Quin groups were analyzed using a 3 3 2 mixed ANOVA
followed by a simple effects test comparing the data obtained in sessions
3 and 5. Paired t tests were conducted between sessions 3 and 4 and
between sessions 4 and 5 on infusions of the SKF1Quin group to
evaluate the effects of the removal and reinstatement of 0.5 mM SKF plus
0.5 mM Quin in the SKF1Quin group. In addition, preference for the
infusion or control lever in the SKF1Quin group was examined using a
2 3 3 ANOVA for the two levers during the first three sessions. The
removal and reinstatement effects of SKF1Quin on responding were
evaluated using 2 3 2 ANOVAs for the two levers between sessions 3 and
4 and between sessions 4 and 5.
Experiment 3, effects of increased lever–response requirements
on the self-infusion of SKF1Quin into the ACB shell
Test condition. To make it easier for rats to learn the response–stimulus
contingency, auditory and visual cues were provided, and the time-out
period was shortened. The initiation of an infusion was accompanied by
activation of a high frequency tone (Sonalert; Coulbourn Instruments,
Inc.) and by the extinguishing of the dim house light. The high frequency
tone and the extinguished house light persisted during the 5 sec infusion
period and the subsequent 5 sec time-out period. Depression of the
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infusion lever did not produce additional infusions during the infusion
and time-out periods. The termination of the auditory cue and reinstate-
ment of the house light signaled the availability of another infusion.
Depression of the control lever had no programmed consequence at any
time. With the fixed-ratio 1 (FR1) schedule, a single depression of the
infusion lever resulted in the delivery of the infusate. With the FR3
schedule, three depressions of the infusion lever were required to deliver
one infusion, except for the first four infusions and the second four
infusions, which were delivered after a single response and after two
responses, respectively. Sessions were 90 min in duration; they were
terminated early if rats self-administered 24 infusions.
Test procedure. Experimentally naive rats (n 5 10) were prepared as
described above. Animals were given the opportunity to self-infuse 0.5
mM SKF plus 0.5 mM Quin into the shell portion of the ACB during three
sessions. The first session was used to acclimate the rats to the test
condition. In the first session, subjects were given the opportunity to
self-infuse SKF1Quin with the FR1 schedule. During the second and
third sessions, the effects of increasing the response requirements were
evaluated; each rat was allowed to self-administer the SKF1Quin mix-
ture with the FR1 and the FR3 schedules. The order of testing the FR1
and FR3 schedules was counterbalanced among subjects.
To evaluate the effects of the two different response requirements, we
conducted a 2 3 2 ANOVA for responses on the two levers during the
two response requirement schedules. Paired t tests were conducted to
evaluate the effects of the two response requirements on infusions and
the time to complete the session.
Experiment 4, effects of D1 and D2 antagonists on the self-
administration of the SKF1Quin mixture into the ACB shell
Experimentally naive rats were prepared as described above. In session
1, the rats were given the opportunity to self-infuse 0.5 mM SKF plus 0.5
mM Quin into the shell region of the ACB; this session was used to
acclimate the subjects to the general test condition described above.
During sessions 2–4, subjects were given the opportunity to self-
administer 0.5 mM SKF plus 0.5 mM Quin, 0.5 mM SKF plus 0.5 mM Quin
containing 0.5 mM SCH 23390, a D1 antagonist (SKF1Quin1SCH), and
0.5 mM SKF plus 0.5 mM Quin containing 0.5 mM sulpiride, a D2
antagonist (SKF1Quin1Sul). The order of testing these three solutions
was counterbalanced among subjects. To evaluate the effects of the D1
and D2 antagonists on the number of self-infusions of the 0.5 mM SKF
plus 0.5 mM Quin mixture, a one-way within-subject design ANOVA was
conducted for the three infusion solutions, followed by a Newman–Keuls
post hoc test.
Histology
At the termination of each experiment, the animals were killed by CO2
inhalation. Black India ink (0.5 ml) was injected into the infusion site; the
brain was removed and frozen. The frozen brain was sliced into 40 mm
sections, using a cryostat microtome. Sections were stained with cresyl
violet.
RESULTS
Experiment 1, intra-ACB self-administration of D1 and
D2 agonists: dose–response analyses
Figure 1 depicts injection sites with shell (lef t) and core (right)
placements. Figure 2 provides photomicrographic evidence dem-
onstrating placements within the shell and core of the ACB.
Figure 3 shows the number of infusions of SKF, Quin, and
SKF1Quin, at concentrations of 0.0, 0.25, 0.50 and 1.0 mM, in the
shell and core of the ACB. Rats reliably self-administered
SKF1Quin into the shell region of the ACB, whereas the solu-
tions of SKF or Quin alone were not reliably self-infused into the
shell. In addition, the SKF1Quin mixture was not significantly
self-administered into the core of the ACB.
Experiment 2, intrashell self-administration of D1 and
D2 agonists: an interactive effect
Figure 4 shows a comparison of the number of infusions obtained
during the first three sessions of groups of rats given SKF alone,
Quin alone, or the mixture of SKF1Quin. The effects of giving
the SKF and Quin groups the mixture of SKF1Quin in sessions
4 and 5 and of substituting vehicle for the mixture in the
SKF1Quin group in session 4 are also shown in Figure 4. The
mixture of SKF1Quin was much more effective in supporting
ICSA behavior than was either compound alone. A between-
subject design comparison revealed that the SKF1Quin group
obtained more infusions than the SKF or Quin groups during the
first three sessions [F(2,20) 5 10.53; p , 0.001]. A mixed ANOVA
with the three groups between sessions 3 and 5 revealed a
group 3 session interaction [F(2,20) 5 4.32; p 5 0.04]. The SKF
and Quin groups obtained more infusions in session 5 when the
mixture of SKF1Quin was made available ( p 5 0.01), whereas
the SKF1Quin group that obtained SKF1Quin in both sessions
3 and 5 maintained similar levels of infusions between the
sessions.
The effect of substituting vehicle for the SKF1Quin mixture
was evaluated in the SKF1Quin group by comparing the number
of infusions in session 3 with the number obtained in session 4.
The rats obtained much lower infusion levels when the
SKF1Quin solution was replaced with vehicle [t(5) 5 2.92; p 5
0.02]. When the SKF1Quin mixture was reinstated in session 5,
the rats again obtained higher levels of infusions compared with
session 4 [t(5) 5 2.15; p 5 0.04].
Figure 5 shows the number of responses on the infusion and
control levers by the SKF1Quin group during the first three
Figure 1. Injection placements in experiment 1. Cannula placements
that were included for shell infusions were depicted on the lef t, whereas
cannula placements included for core infusions were depicted on the right.
The numbers on the right indicate distances (in millimeters) from bregma.
The drawings are based on the rat brain atlas of Paxinos and Watson
(1986), and the divisions between the shell and core are based on the
study by Jongen-Relo et al. (1994). Co, Core; CPu, caudate putamen; Sh,
shell.
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sessions when the SKF1Quin mixture was available, during ses-
sion 4 when vehicle was substituted for the mixture, and after
reinstatement of the mixture in session 5. When a within-subject
design was used, rats exhibited a statistically reliable preference
( p 5 0.01) for the infusion lever over the control lever during the
first three sessions. This difference was not evident when vehicle
was substituted for the mixture in session 4.
Experiment 3, effects of increased lever–response
requirements on the self-infusion of SKF1Quin into
the ACB shell
Figure 6 illustrates the effects of increasing the response require-
ments from FR1 to FR3 on the number of responses on the
infusion and control levers, on the number of infusions, and on
the time needed to complete the test sessions. The two schedules
had a differential effect on response levels with the two levers
collapsed together ( p 5 0.02). In addition, rats responded more
on the infusion lever than on the control lever [F(1,9) 5 6.24; p 5
0.03]. The lever 3 schedule interaction was not reliable. The
number of infusions delivered with the two different schedules
was not different [t(9) 5 1.47; p 5 0.2]; the time needed to
complete the sessions with either schedule was not significantly
different [t(9) 5 1.90; p 5 0.09].
Experiment 4, effects of D1 and D2 antagonists on the
self-administration of the SKF1Quin mixture into the
ACB shell
Figure 7 shows the effects of including D1 and D2 antagonists in
the infusate on the ICSA of the SKF1Quin solution into the
ACB shell. Coadministration of either the D1 antagonist SCH
23390 or the D2 antagonist sulpiride abolished the intrashell
self-administration of SKF1Quin [F(2,17) 5 12.84; p 5 0.002].
DISCUSSION
The major findings of the present study suggest that concurrent
activation of D1- and D2-type receptors in the shell, but not core,
region of the ACB produces a cooperative effect on operant
reinforcement behavior. This conclusion is supported by the
findings that none of the individual concentrations of SKF and
Quin were capable of supporting ICSA behavior in the ACB,
whereas the combination of SKF plus Quin produced reliable
self-infusions only in the shell portion of the ACB (Fig. 3).
Furthermore, the low infusions obtained with either the D1 or D2
agonist alone were not caused by misplacement of the injection
cannula because rats in the SKF and Quin groups exhibited
heightened levels of infusions when given the SKF1Quin mix-
ture (Fig. 4).
Interaction of D1- and D2-type receptors
The interaction of DA D1- and D2-type receptors has been
reported on a variety of measures (see Clark and White, 1987;
Waddington et al., 1994). The cooperative effect of the
SKF1Quin mixture on intra-accumbens self-infusions is in gen-
eral agreement with findings on motor activation produced by
manipulations of ACB DA or DA receptors. In general, microin-
jection of either a D1 or D2 agonist alone into the ACB had little
or no effect on motor activity, whereas concurrent injection of a
D1 and D2 agonist into the ACB increased motor activity
(Plaznik et al., 1989; Essman et al., 1993; Koshikawa et al.,
1996a). The heightened locomotor activity produced by concur-
rent D1 and D2 agonists was attenuated by coadministration of
either a D1 or D2 antagonist (Plaznik et al., 1989; Koshikawa et
al., 1996a).
Coadministration of either the D1 antagonist SCH 23390 or the
D2 antagonist sulpiride abolished the intrashell self-infusion of
the mixture of D1 and D2 agonists (Fig. 7). These data support
the idea that concurrent activation of D1- and D2-type receptors
is involved in DA-mediated reinforcement processes within the
ACB. Findings from the ICSA studies of Phillips et al. (1994) and
the brain electrical self-stimulation experiments of Kurumiya and
Nakajima (1988) and Nakajima (1989) are in agreement with this
interpretation. Phillips et al. (1994) reported that coadministra-
tion of the D1 antagonist SCH 23390 or the D2 antagonist
sulpiride decreased the rewarding effects of self-infusion of am-
phetamine into the ACB. Microinjection of either the D2 antag-
onist raclopride or the D1 antagonist SCH 23390 alone into the
ACB diminished brain electrical self-stimulation behavior (Ku-
rumiya and Nakajima, 1988; Nakajima, 1989).
Mechanisms underlying the cooperative effects of activating
DA D1 and D2 receptors have not been clearly identified. One
possible mechanism to explain the present results is that con-
current activation of both D1 and D2 receptors on certain
populations of neurons may be needed to mediate reinforce-
ment. There are subpopulations of ACB neurons that seem to
contain both D1- and D2-type receptors (White and Wang,
1986; Le Moine and Bloch, 1996; Shetreat et al., 1996). In
addition, there are some neurons in the ACB that are inhibited
to a greater extent with simultaneous application of D1 and D2
agonists than with either agonist alone (White and Wang,
1986; White, 1987).
In the present study, both agonists need to be given to maintain
reliable self-infusions because the endogenous extracellular levels
of DA may be too low at key synapses to activate a sufficient
number of D1 receptors to enable D2 receptors when only the D2
agonist is available. A similar argument could be used for the low
self-infusions of the D1 agonist alone. Furthermore, intra-
accumbens infusion of Quin is likely to reduce endogenous DA
release by stimulating presynaptic D2 autoreceptors (Imperato
and Di Chiara, 1988).
Figure 2. Photomicrographs showing a shell and core placement in the
ACB. A, A typical shell placement that supported a high level of self-
infusion of SKF1Quin. B, A core placement that supported a low level of
self-infusion of SKF1Quin.
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Contrary to the present findings, White et al. (1991) reported
that injection of either a D1 or D2 agonist alone into the ACB
produced place-preference conditioning. Some factors that could
contribute to the differences between the two studies were the
high doses used in the place-preference study and the types of
behaviors being measured. White et al. (1991) injected nanomole
quantities (2–10 nmol/0.5 ml) of SKF 38393 and quinpirole into
the anterior and middle regions of the ACB, primarily within the
shell, to produce conditioned place preference. This concentra-
tion is several-fold higher than the picomole amounts that were
used in the present study. At these higher doses, SKF and Quin
could be having nonselective effects. In the present experiments,
the concentrations of the individual agonists seem to be high
enough to produce a pharmacological effect. For example, the
combination of 0.25 mM SKF plus 0.25 mM Quin produced
significantly more self-infusions above vehicle than did either 1.0
mM SKF or 1.0 mM Quin alone (Fig. 3). If 0.25 mM agonist in the
mixture is sufficient to produce self-administration behavior, then
1.0 mM agonist, when given alone, should also be effective, unless
activation of both D1 and D2 receptors is required to maintain
ICSA behavior.
A second explanation for the apparent contradictory findings of
the study of White et al. (1991) and the present study is that
different neural mechanisms may be regulating reinforcement
measured with operant responding and reinforcement measured
with place conditioning. In the case of the place-conditioning
task, activation of only one type of DA receptor may be needed.
Nanomole amounts of amphetamine (Hoebel et al., 1983; Phil-
lips et al., 1994) and nomifensine (Carlezon et al., 1995) were
needed to support ICSA behavior, whereas, in the present study,
the amounts of SKF and Quin required in the mixture to support
ICSA were approximately 5–20-fold lower. The likely reason for
this is that lower amounts of the direct-acting agonists are needed
to produce effects similar to those caused by the indirect-acting
DA agonists.
There are reports that rats and monkeys can maintain intrave-
nous self-administration of either the D1- or D2-type agonist
alone (e.g., Woolverton et al., 1984; Wise et al., 1990; Self and
Stein, 1992; Grech et al., 1996). These findings suggest that
activation of only one subtype of receptor may be needed to
maintain DA-mediated reinforcement behavior. However, com-
paring results from systemic self-administration experiments with
data obtained using the ICSA procedure is difficult, because any
behavioral effect observed after systemic administration may be
caused by a net effect produced by a compound acting at multiple
CNS sites.
Functional dissociation of the shell and core
The present study found the shell region of the ACB supported
the self-administration of the mixture of DA agonists, whereas
Figure 3. Intra-ACB self-administration
of D1 and D2 agonists: dose–response
analyses. Rats were assigned to one of
three infusate groups: SKF, Quin, or
SKF1Quin. During four sessions (3 hr/
session), animals were given the opportu-
nity to respond to vehicle and three con-
centrations (25, 50, and 100 mM) of one of
the infusate types. One-way ANOVAs
over four concentrations of infusion solu-
tions revealed that the treatment of SKF
alone [n 5 9; F(3,24) 5 2.50] or Quin alone
[n 5 10; F(3,27) 5 2.01] into the shell or
SKF1Quin into the core [n 5 7; F(3,18) 5
2.57] did not produce a statistically reli-
able effect on infusions, whereas the treat-
ment of SKF1Quin into the shell (n 5 9)
produced heightened levels of infusions
[F(3,24) 5 7.28; p 5 0.001]. *p , 0.01
compared with vehicle. Data are the
mean 6 SEM.
Figure 4. Intrashell self-administration of D1 and D2 agonists: an inter-
active effect. Rats were assigned to one of three groups. The SKF group
(n 5 7) received 0.5 mM SKF during the first three sessions and the
mixture of 0.5 mM SKF plus 0.5 mM Quin (SKF1Quin) in sessions 4 and
5. Similarly, the Quin group (n 5 10) received infusions of 0.5 mM Quin
in sessions 1–3, followed by infusions of 0.5 mM SKF plus 0.5 mM Quin in
sessions 4 and 5. The SKF1Quin group (n 5 6) received infusions of 0.5
mM SKF plus 0.5 mM Quin in sessions 1–3 and 5; in session 4, only vehicle
was available. During sessions 1–3, rats receiving SKF1Quin obtained
more infusions than did rats receiving SKF or Quin alone ( p , 0.001).
The SKF and Quin groups exhibited higher levels of self-infusion in
session 5, when SKF1Quin was given in place of SKF or Quin alone, than
in session 3 ( p 5 0.01). The replacement of SKF1Quin with vehicle in
the SKF1Quin group in session 4 diminished self-infusions ( p 5 0.02),
whereas the group exhibited higher self-infusions in session 5 when
SKF1Quin was reinstated ( p 5 0.04). Data are the mean 6 SEM.
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the core did not (Fig. 3). These results are in agreement with
reports that rats self-administer nomifensine (Carlezon et al.,
1995) and amphetamine (Hoebel et al., 1983) into the ACB shell
region.
Contrary to the above findings, the study of Phillips et al. (1994)
suggested that the core portion of the ACB may mediate amphet-
amine self-administration. However, their injection sites ap-
peared to be near the boundary of the core and shell, and
diffusion of the amphetamine into the shell region could account
for their results.
The shell portion of the ACB receives its major DA input from
the VTA and is considered to be involved in mediating motivated
behaviors; the core receives significant DA inputs from the sub-
stantia nigra and is considered to be important in regulating
motor activity (for review, see Kalivas et al., 1993). Thus, the
present ICSA studies are consistent with an interpretation that
activation of DA receptors within the shell portion of the ACB
enhances goal-directed behavior.
Goal-directed effect of ACB infusions
One major concern of the ICSA paradigm is whether self-
administration behavior is an artifact produced by an enhance-
ment of general motor activity. Indeed, microinjection of DA
agonists into the ACB has been shown to produce heightened
locomotor activity (see references cited above). Disoriented mo-
tor arousal, however, does not explain the heightened infusions
and responses observed in the present study. First, the levers were
Figure 5. Lever responses by the SKF1Quin group during acquisition,
extinction, and reinstatement sessions. Data are the mean 6 SEM. A
within-subject experimental design revealed that rats given 0.50 mM SKF
plus 0.50 mM Quin showed reliable preference for the infusion lever over
the control lever during the first three sessions [F(1,3) 5 13.55; p 5 0.01].
It should be noted that the relatively large SEM values were mainly
because of the variability among subjects. Within subjects, preference for
the infusion lever over the control lever was consistent. The rats exhibited
a reduction in lever responses when SKF1Quin was replaced with vehicle
in session 4 [the main effect of schedules, F(1,5) 5 7.31; p 5 0.04].
Although not statistically reliable, rats tended to increase lever responses
when SKF1Quin was reinstated in session 5 [the main effect of schedules,
F(1,5) 5 4.61; p 5 0.085].
Figure 6. Effects of increased lever–response requirements on the self-
infusion of the SKF1Quin mixture into the ACB shell. Rats (n 5 10)
were given the opportunity to self-administer the mixture of 0.5 mM SKF
plus 0.5 mM Quin over two sessions. As shown in A, rats exhibited a higher
level of lever responses under the FR3 schedule than under the FR1
schedule with the levers collapsed together [F(1,9) 5 8.19; p 5 0.02]; rats
also exhibited a reliable lever preference for the infusion lever over the
control lever with the schedules collapsed together [F(1,9) 5 6.24; p 5
0.03]; and the lever 3 FR schedule interaction was not reliable [F(1,9) 5
2.56]. There was no reliable difference between the schedules in the
number of infusions [B; t(9) 5 1.47] or in the time needed to complete the
session [C; t(9) 5 1.90]. Data are the mean 6 SEM.
Figure 7. Effects of D1 and D2 antagonists on the intrashell self-
administration of SKF1Quin. During three sessions, rats (n 5 6) were
given the opportunity to self-administer the mixture of 0.5 mM SKF plus
0.5 mM Quin (SKF1Quin) or the SKF1Quin mixture containing either
0.5 mM SCH 23390 (SKF1Quin1SCH) or 0.5 mM sulpiride
(SKF1Quin1Sul). The presence of the D1 antagonist SCH or the D2
antagonist Sul significantly reduced intrashell self-infusion of SKF1Quin
(*p , 0.01). Data are the mean 6 SEM.
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placed on a relatively high level from the floor; rats needed to rear
to depress the lever. Thus, it seems unlikely that simply moving
about the operant chamber could result in reliable high lever
responding by many subjects across multiple sessions. Second, in
experiment 2, the rats self-administrating the mixture of the D1
and D2 agonists exhibited a reliable preference for the lever
producing infusions over the lever without consequence (Fig. 5).
In addition, this preference cannot be explained by asymmetrical
movements that unilateral infusions may have produced, because
the position of the infusion lever between left and right was
counterbalanced among subjects. Third, in experiment 3, rats
exhibited an adaptive response when a higher response require-
ment was instituted. Enhanced lever responding was observed
when the fixed-ratio requirement was increased from FR1 to FR3;
no changes in infusion levels and the time to complete sessions
were observed between the FR1 and FR3 schedules (Fig. 6). A
reliable preference for the infusion lever over the control lever
was observed under both schedules in this experiment. In sum-
mary, the results suggest a goal-directed effect of the combination
of D1 and D2 agonists infused into the ACB.
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